Disclosures for "Efficacy, Safety, and Tolerability of Adjunctive Eslicarbazepine Acetate in Focal Seizure Patients With Focal to Bilateral Tonic-Clonic Seizures at Baseline")
-
The institution of Dr. Chung has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ucb pharma. Dr. Chung has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SK Life sciences. Dr. Chung has received personal compensation in the range of $500-$4,999 for serving as a Consultant for eisai. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for eisai. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for ucb. Dr. Chung has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK Life sciences. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for sunovion.
-
Samy Guirguis has nothing to disclose.
-
Dr. Cantu has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
-
Joana Moreira has received personal compensation for serving as an employee of BIAL.
-
Luis Magalhaes has received personal compensation for serving as an employee of BIAL-Portela & Cª, S.A..
-
Ms. Hall has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
-
Ian Zhang has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
-
Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..